Evidence map›Paper›PMID 39040102›Full record

ArticleFrontiers in immunology2024

Dual roles of CD11b

Ming Ni, Jing Cui, Xin Yang, Yuntian Ding, Peng Zhao, Tianzhen Hu, Yun Zhan, Qian Kang, Xiuying Hu, Jiangyuan Zhao and 14 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Ming Ni *Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jing Cui *Department of Dermatology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xin YangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yuntian DingDepartment of Internal Medicine V, University Clinic Heidelberg, Heidelberg, Germany.
Peng ZhaoDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Tianzhen HuDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yun ZhanDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Qian KangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xiuying HuDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Jiangyuan ZhaoDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Yao XuDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Lu ChenDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Min LiuDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Mei ZhaoDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Fengqi ZhangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Shisi HuangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Ya LiDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Xueying YangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Luxin ZhangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Tianzhuo ZhangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Bo DengDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Bing YangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.
Deqin LuDepartment of Pathophysiology, Guizhou Medical University, Guiyang, China.
Jishi WangDepartment of Hematology, Affiliated Hospital of Guizhou Medical University, Guiyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Granulocytic myeloid-derived suppressor cells (G-MDSCs) show fast recovery following allogeneic hematopoietic stem cell transplantation (allo-HSCT) constituting the major part of peripheral blood in the early phase. Although G-MDSCs mediate immune suppression through multiple mechanisms, they may also promote inflammation under specific conditions. Methods: G-MDSCs were isolated from 82 patients following allo-HSCT within 90 days after allo-HSCT, and their interactions with autologous CD3 Results: G-MDSCs promoted inflammation in the early-stage, by facilitating cytokine secretion and proliferation of T cells, as well as their differentiation into pro-inflammatory T helper subsets. At day 28, patients with a higher number of G-MDSCs exhibited an increased risk of developing grades II-IV aGvHD. Besides, adoptive transfer of G-MDSCs from patients at day 28 into humanized mice exacerbated aGvHD. However, at day 90, G-MDSCs led to immunosuppression, characterized by upregulated expression of indoleamine 2,3-dioxygenase gene and interleukin-10 secretion, coupled with the inhibition of T cell proliferation. Furthermore, transcriptional analysis of G-MDSCs at day 28 and day 90 revealed that 1445 genes were differentially expressed. These genes were associated with various pathways, revealing the molecular signatures of early post-transplant differentiation in G-MDSCs. In addition, genes linked to the endoplasmic reticulum stress were upregulated in patients without aGvHD. The acquisition of immunosuppressive function by G-MDSCs may depend on the activation of Conclusion: Our findings revealed the alteration in the immune characteristics of G-MDSCs within the first 90 days post-allo-HSCT. Moreover, the quantity of G-MDSCs at day 28 may serve as a predictive indicator for the development of aGvHD.

Indexed as

Hematopoietic Stem Cell TransplantationMyeloid-Derived Suppressor CellsTransplantation, HomologousAdolescentAdultAnimalsCD11b AntigenFemaleGraft vs Host DiseaseGranulocytesHLA-DR AntigensHumansInflammationMaleMiceMiddle AgedCD11b AntigenHLA-DR AntigensaGVHDallo-HSCTER-stressG-MDSCsHO-1immunomodulationT cells

Identifiers

PMID39040102
PMCPMC11260618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.